Prelude Therapeutics Inc
$ 5.52
25.45%
15 Apr - close price
- Market Cap 276,607,000 USD
- Current Price $ 5.52
- High / Low $ 5.54 / 4.26
- Stock P/E N/A
- Book Value 0.83
- EPS -1.29
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -0.99 %
- 52 Week High 5.54
- 52 Week Low 0.73
About
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$5.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-12 | 2025-08-14 | 2025-05-05 | 2025-02-13 | 2024-10-30 | 2024-08-12 | 2024-05-07 | 2024-02-15 | 2023-11-01 | 2023-08-03 | 2023-05-08 |
| Reported EPS | -0.2 | -0.26 | -0.41 | -0.42 | -0.37 | -0.43 | -0.46 | -0.42 | -0.46 | -0.45 | -0.54 | -0.58 |
| Estimated EPS | -0.13 | -0.3697 | -0.48 | -0.48 | -0.4673 | -0.47 | -0.43 | -0.48 | -0.49 | -0.58 | -0.63 | -0.68 |
| Surprise | -0.07 | 0.1097 | 0.07 | 0.06 | 0.0973 | 0.04 | -0.03 | 0.06 | 0.03 | 0.13 | 0.09 | 0.1 |
| Surprise Percentage | -53.8462% | 29.6727% | 14.5833% | 12.5% | 20.8217% | 8.5106% | -6.9767% | 12.5% | 6.1224% | 22.4138% | 14.2857% | 14.7059% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRLD
2026-04-15 12:11:02
Prelude Therapeutics Inc. has announced the appointment of Dr. Charles Morris as Executive Vice President and Chief Medical Officer, effective April 20, 2026. Dr. Morris brings over 30 years of oncology drug development experience and will be instrumental as Prelude advances two lead programs into clinical development in 2026. His compensation package includes an annual base salary of $535,000, a target bonus, and options to purchase 450,000 shares of common stock.
2026-04-15 11:11:02
Prelude Therapeutics has appointed Dr. Charles Morris as its new Chief Medical Officer, effective April 20, 2026. Morris brings extensive oncology drug development experience and will play a key role as the company advances two lead programs into clinical development in 2026, targeting myeloproliferative neoplasms and ER+ breast cancer. The company has seen a significant return over the past year and continues to progress its pipeline, including a recently cleared Phase 1 study for PRT12396.
2026-04-15 11:11:02
Prelude Therapeutics has announced the appointment of Dr. Charles Morris as their Chief Medical Officer, effective April 20, 2026. Dr. Morris brings over 30 years of oncology drug development experience from various global biotech and pharmaceutical companies. His leadership is expected to be instrumental as Prelude advances its lead programs targeting myeloproliferative neoplasms and ER+ breast cancer into clinical development in 2026.
2026-04-03 16:39:24
This NASDAQ page provides live quotes and charts for Prelude Therapeutics Incorporated (PRLD) stock, indicating a current price of $3.83 with a 10.69% increase. The page also notes that current analyst ratings and earnings information for PRLD are unavailable. It features various trading resources and promotional content for a trading platform.
2026-04-02 04:40:19
This article from MSN is incomplete and does not contain any content about Prelude Therapeutics' 2025 results or its oncology pipeline. Therefore, a meaningful summary cannot be generated from the provided text.
2026-04-01 05:41:10
This article reports on Prelude Therapeutics' 2025 financial results and updates on its oncology pipeline. The company is advancing several drug candidates through clinical trials, focusing on treatments for various cancers. Key updates include progress in their PRT1419, PRT2527, and PRT3645 programs.
